• Letters from CAMP Rehoboth
    • Current Issue
    • Past Issues
    • Advertising Information
    • Where Can I Get Letters?
    • The Write Stuff
  • Events
    • Featured Events
    • Past Events
    • Current Classes + Events
    • Women's FEST
  • Programs
    • Arts & Culture
    • Education & Advocacy
    • Health & Wellness
    • Community Building
    • CAMP Facilities
  • About Us
    • Membership
    • Volunteers
    • Board of Directors
    • CAMP Rehoboth Staff
    • Reports and Financials
    • History
    • Employment Opportunities
    • Press
  • Resources
    • Beach Guide Directory
    • LGBTQ Resources
    • LGBTQ Providers
    • LGBTQ Delaware Data
    • Trans & Nonbinary Resources
    • BIPOC LGBTQ Resources
    • LGBTQ Local and National Resources Guide
  • Contact
  • Shop
close× Call Us 302-227-5620
close×

Search form

August 23, 2019 - Health and Wellness by Marj Shannon

Be PrEPared!

There’s good news on the pre-exposure prophylaxis (PrEP) front! Not that PrEP alone isn’t great news. After all, what’s not to love about a daily medicine (Truvada®) that reduces the risk of getting HIV from sex by more than 90 percent? (Among people who inject drugs, it reduces risk by more than 70 percent.) Combined with condoms (“PrEP + 1”), your risk of getting HIV from sex can be lowered even further.

So—the current good news: soon, more people may be able to afford the drug—which is important, given it has an annual price tag (before discounts provided to insurers) of about $21,000. Although many insurers cover the drug, it may carry a high enough co-pay that potential users cannot access it. What happened to improve that situation?

In June 2019, the US Preventive Services Task Force recommended that physicians offer PrEP to people at high risk of contracting human immunodeficiency virus (HIV). Recommendations made by the task force have implications for health insurers: As a result of this recommendation, starting in 2021, most health plans will be required to cover drugs recommended to prevent HIV, and patients cannot be charged anything out-of-pocket for the medication.

This could result in a real uptick in the number of people taking the drug. And that would be a very good thing: The Centers for Disease Control and Prevention (CDC) has estimated that 1.1 million people in the US could benefit from taking Truvada. Gilead, the biotechnology company which developed and holds the patent on Truvada, reported that during the second quarter of 2019 about 213,000 people were taking the drug for HIV prevention. That means that just under 20 percent of those people who could benefit are actually taking the drug. Clearly, there’s room for improvement.

There’s more good news, too: A generic version of Truvada is scheduled to be available in the US in September 2020, with more generic versions expected in 2021. Often, the availability of generic versions of drugs drives prices down.

Of course, some barriers to access remain: Truvada is available only by prescription, and requires both pre-prescribing laboratory testing and quarterly laboratory monitoring. Typically, obtaining orders for that testing—as well as prescriptions for Truvada—require physician (or clinic) office visits. The costs of both office visits and laboratory testing may—or may not—be covered by insurance.

In related news: Gilead hopes soon to be marketing a newer drug, Descovy, for HIV prevention. (The drug was approved in 2016 for treating people who already have HIV.) In early August, a US Food and Drug Administration (FDA) advisory panel recommended the agency approve the drug for prevention purposes. Descovy has been shown in clinical trials to be less toxic to the bones and kidneys than Truvada. At least for patients whose bones or kidneys are deemed to be at risk from Truvada, Descovy may provide an alternative.

Interested in learning more or in talking with a health care provider about PrEP? CAMP Rehoboth can help!

Contact Health & Wellness Director Salvatore Seeley (302-227-5620) to talk about what’s available and how to connect with resources. We offer HIV (and other STI) testing, and referrals to LGBTQ-friendly health care navigators who are familiar with PrEP. These individuals can prescribe PrEP and the periodic lab testing its use requires, and can even help you find resources to pay for the drug if your insurer does not cover it.

More News on the Prevention Front

On June 26 of this year, a CDC advisory committee recommended that adults age 27 to 45 who have not been vaccinated against human papilloma virus (HPV) should receive the vaccine. Why is that important? Because infection from HPV, which is a group of more than 100 related viruses, is a major risk factor for six types of cancer.

HPV causes cancer in both women and men, with about 60 percent of these cancers occurring among women. The six cancers are: cervical, vaginal, and vulvar cancers; penile cancer; and anal and back-of-the-throat cancers.

Cancer of the cervix is the most common HPV-related cancer among women, accounting for just over half (53 percent) of the 20,300 HPV-related cancer cases reported among women as of August 2018. Vulvar and vaginal cancers accounted for 16 percent; anal cancer for 20 percent; and back-of-the-throat cancer for 11 percent.

Back-of-the-throat cancer is the most common HPV-related cancer among men, accounting for 80 percent of the 13,400 HPV-related cancer cases reported among men as of August 2018. Anal cancer accounted for 14 percent, and penile cancer for 6 percent.

So—where’s the good news in all that?! Right here: These HPV-related cancers are largely preventable! And not by something really unappealing like, say, abstinence.

They are prevented by that aforementioned vaccination. There is a two-dose series for children who are 11 or 12 years of age (or younger) when they receive the first dose; the second dose is given six to 12 months later. For people who start the series at age 15 or older, there is a three-dose series given over a period of six months.

Vaccination is recommended for:

→ Girls and boys 11 or 12 years of age (or as young as nine).
→ Females age 13-26 years of age and males 13-21 years of age who have not started the vaccines or who started—but did not complete—the series. Males age 22-26 years can also be vaccinated.
→ Men who have sex with men (through 26 years of age).
→ People with weakened immune systems, including those with HIV, if they have not previously been vaccinated.
→ Young adults who are transgender.
→ And now, also for people 27 to 45 years of age who have not previously been vaccinated.

Since their introduction, the vaccines have proven their effectiveness. For example, among teen girls, infections with HPV types that cause most HPV cancers have dropped 71 percent; among young adult women, these rates of infection have dropped 61 percent.

Fall into one of the groups recommended for vaccination? Talk to your health care provider! And if you don’t—maybe you have a child or grandchild or other family member or friend who does. Talk to them. Make sure they’re aware the vaccine is readily available—and can be a real life-saver. ▼

Is PrEP right for you?

The Centers for Disease Control and Prevention (CDC) says it might be, if you fit into any of the below categories:

You are HIV negative AND you are a gay or bisexual man who:

Has an HIV-positive partner or Has multiple partners, a partner with multiple partners, or a partner whose HIV status is unknown—and you also: Have anal sex without a condom, or Recently had a sexually transmitted infection (STI).

You are HIV negative AND a heterosexual (man or woman) who:

Has an HIV-positive partner; or Has multiple partners, a partner with multiple partners, or a partner whose HIV status is unknown—and you also: Don’t always use a condom for sex with people who inject drugs or Don’t always use a condom for sex with bisexual men.

You are HIV negative AND you inject drugs AND you:

Share needles or equipment to inject drugs; Recently went to a drug treatment program; or Are at risk for getting HIV from sex.

Marj is an epidemiologist and wordsmith who has devoted her life to minutiae. She reports that yes, the devils are in the details. Aren’t they always?

‹ August 23, 2019 - Disco Lottery by Sondra N. Arkin up August 23, 2019 - CAMPshots Gallery 1 ›

Past Issues

Issues Index

  • November 15, 2019 - Issue Index
  • October 18, 2019 - Issue Index
  • September 20, 2019 - Issue Index
  • August 23, 2019 - Issue Index
    • August 23, 2019 - Cover-to-cover with ISSUU
    • August 23, 2019 - The Way I See It by Murray Archibald
    • August 23, 2019 - In Brief
    • August 23, 2019 - CAMPmatters by Murray Archibald
    • August 23, 2019 - CAMP Out by Fay Jacobs
    • August 23, 2019 - CAMP Stories by Rich Barnett
    • August 23, 2019 - The Real Dirt by Eric W. Wahl
    • August 23, 2019 - Community News
    • August 23, 2019 - All About Sundance
    • August 23, 2019 - Drag Volleyball by Fay Jacobs
    • August 23, 2019 - President's View by Chris Beagle
    • August 23, 2019 - CAMP News
    • August 23, 2019 - AIDS Walk Delaware by JulieAnne Cross
    • August 23, 2019 - It's My Life by Michael Thomas Ford
    • August 23, 2019 - CAMP Critters
    • August 23, 2019 - Historical Headliners by Ann Aptaker
    • August 23, 2019 - Sporty Gals by Anita Pettitt
    • August 23, 2019 - Straight Talk by David Garrett
    • August 23, 2019 - Eating OUT by Fay Jacobs
    • August 23, 2019 - Disco Lottery by Sondra N. Arkin
    • August 23, 2019 - Health and Wellness by Marj Shannon
    • August 23, 2019 - CAMPshots Gallery 1
    • August 23, 2019 - CAMPshots Gallery 2
    • August 23, 2019 - CAMPshots Gallery 3
    • August 23, 2019 - Out & Proud by Stefani Deoul
    • August 23, 2019 - Sundance Elves
    • August 23, 2019 - Out & About by Eric C. Peterson
    • August 23, 2019 - CAMP Cheers!
    • August 23, 2019 - CAMP Arts by Doug Yetter
    • August 23, 2019 - Booked Solid by Terri Schlichenmeyer
    • August 23, 2019 - Screen Queen
    • August 23, 2019 - CAMP Dates - August 17 - October 13
    • August 23, 2019 - Deep Inside Hollywood
  • August 9, 2019 - Issue Index
  • July 26, 2019 - Issue Index
  • July 12, 2019 - Issue Index
  • June 28, 2019 - Issue Index
  • June 14, 2019 - Issue Index
  • May 31, 2019 - Issue Index
  • May 17, 2019 - Issue Index
  • May 3, 2019 - Issue Index
  • April 12, 2019 - Issue Index
  • March 8, 2019 - Issue Index
  • February 8, 2019 - Issue Index

Follow Us

Follow us on Social Media!

RECEIVE WEEKLY EMAIL

Information

  • Letters
  • Events
  • About Us
  • CAMP Center

Support CAMP

  • CAMP Membership
  • Volunteer
  • Contact Us
  • Donate
Copyright © CAMP Rehoboth, 2022
  • p. 302-227-5620
  • info@camprehoboth.com
  • 37 Baltimore Avenue, Rehoboth Beach, DE 19971